11:56 AM EDT, 04/28/2025 (MT Newswires) -- Kura Oncology ( KURA ) said Monday the first patients have been dosed in phase 1 trial of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors after imatinib failure.

The combination showed robust and durable antitumor activity in preclinical models, the company said.

After completion of the dose-escalation portion of the trial, Kura said it plans expansion cohorts to further assess the safety, tolerability, and clinical activity of ziftomenib.

Price: 6.45, Change: +0.02, Percent Change: +0.23